Image via CrunchBaseAgain another winning prediction from my FDA calendar for October. Expect large gains for Alkermes tomorrow. I wouldn't sell the stock as they have another approval up on Oct. 22nd in conjunction with Amylin and Eli Lilly for Bydureon, a weekly injectible diabetes medication. I expect a FDA approval for that one too. But you never know with the FDA. Amylin already has approvals for daily injections but has modified the technology for weekly injections, so again I anticipate its approval as well. Good news for Alkermes.
Try Wikinvest here--http://www.wikinvest.com/
Wikinvest---Alkermes (ALKS)
Wikinvest--Amylin Pharmaceuticals (AMLN)
If you would like more Subscribe To BioPharma Investor for everyday stock news and up to date FDA decisions. Biopharma Investor
Alkermes addiction drug wins wider U.S. approval
Tue Oct 12, 2010 7:26pm EDT
* Vivitrol already used in U.S. for alcoholics
* Approval may help turn around money-losing drug
* Shares up nearly 69 percent in 2010
* Shares up another 4.2 percent after hours
